Roche reports that the phase III STARGLO study evaluating its Columvi (glofitamab) in patients with relapsed or refractory diffuse large B-cell lymphoma met its primary endpoint of overall survival.

Columvi, in combination with GemOx chemotherapy, demonstrated a statistically significant improvement in overall survival compared to patients treated with MabThera/Rituxan (rituximab) in combination with GemOx.

The safety of the Columvi-GemOx combination appeared consistent with the known profiles of the individual drugs. Data will be submitted to health authorities and shared at a future medical meeting.

Copyright (c) 2024 All rights reserved.